Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | MMP14 | P50281 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1851345 | 0.99 | RECQL (0.39) | RECQLCA2ALDH1A1HSPD1BLM | |
| SCHEMBL27841314 | 0.97 | RECQL (0.38) | RECQLCA2ALDH1A1HSPD1BLM | |
| Ammonia Solution, Strong SCHEMBL27719586 | 0.97 | RECQL (0.38) | RECQLCA2ALDH1A1HSPD1BLM | |
| SCHEMBL28105646 | 0.97 | RECQL (0.38) | RECQLCA2ALDH1A1HSPD1BLM | |
| SCHEMBL5574911 | 0.97 | RECQL (0.38) | RECQLCA2ALDH1A1HSPD1BLM | |
| SCHEMBL967767 | 0.97 | RECQL (0.38) | RECQLCA2ALDH1A1HSPD1BLM | |
| SCHEMBL28850737 | 0.97 | RECQL (0.38) | RECQLCA2ALDH1A1HSPD1BLM | |
| SCHEMBL9326629 | 0.97 | RECQL (0.38) | RECQLCA2ALDH1A1HSPD1BLM | |
| SCHEMBL27708910 | 0.97 | RECQL (0.38) | RECQLCA2ALDH1A1HSPD1BLM | |
| SCHEMBL27945873 | 0.97 | RECQL (0.38) | RECQLCA2ALDH1A1HSPD1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6884792-B2 | Bretylium compositions and kits and their use in preventing and treating cardiovascular conditions | BACANER MARVIN B (US) | 2005-04-26 | — | — | US | disclosed |
| EP-1140054-B1 | BRETYLIUM COMPOSITIONS AND KITS, AND THEIR USE IN PREVENTING AND TREATING CARDIOVASCULAR CONDITIONS | BACANER MARVIN B (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20030119794-A1 | Novel bretylium compositions and kits and their use in preventing and treating cardiovascular conditions | BACANER MARVIN B (US) | 2003-06-26 | — | — | US | disclosed |
| US-6482811-B1 | Bretylium compositions and kits, and their use in preventing and treating cardio-vascular conditions | BACANER MARVIN B (US) | 2002-11-19 | — | — | US | disclosed |
| EP-1140054-A2 | BRETYLIUM COMPOSITIONS AND KITS, AND THEIR USE IN PREVENTING AND TREATING CARDIOVASCULAR CONDITIONS | Bacaner, Marvin B. (US) | 2001-10-10 | — | — | EP | disclosed |
| US-20010008896-A1 | Administration of active agents, including 5-HT receptor agonists and antagonists, to treat premature ejaculation | SMITH WILLIAM L (US) | 2001-07-19 | — | — | US | disclosed |
| WO-2000040232-A2 | BRETYLIUM COMPOSITIONS AND KITS, AND THEIR USE IN PREVENTING AND TREATING CARDIOVASCULAR CONDITIONS | BACANER MARVIN B (US) | 2000-07-13 | — | — | WO | disclosed |
| EP-0911690-A1 | Photothermographic elements adapted for laser exposure | FUJI PHOTO FILM CO., LTD. (JP) | 1999-04-28 | — | — | EP | disclosed |
| US-5759436-A | THICKENER-FREE; ALKYLENE GLYCOL AND OXYALKYLENE GLYCOL MIXTURE | BASF AKTIENGESELLSCHAFT (DE) | 1998-06-02 | — | — | US | disclosed |
| EP-0713514-B1 | AIRCRAFT DE-ICING AND ANTI-ICING AGENTS | BASF AG (DE) | 1998-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119794-A1 | Novel bretylium compositions and kits and their use in preventing and treating cardiovascular conditions | TNNT2, TNNI3, FABP3 | RECQL 2671/4885CA2 1647/4885ALDH1A1 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.